Innate immune signaling in cardiac ischemia

Nature Reviews Cardiology

Volumn 8, Issue 5, 2011, Pages 292-300

  Arslan, Fatih ^a   De Kleijn, Dominique P ^b   Pasterkamp, Gerard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC MYOSIN; FIBRONECTIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HYALURONIC ACID; TOLL LIKE RECEPTOR;

HEART FAILURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW;

ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 79955484855     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.38     Document Type: Review

References (120)

1. Virchow, R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI-Atheromatous affection of arteries. 1858. Nutr. Rev. 47, 23-25 (1989).
2. Van, A. W. I. Landerer's mechanical theory of inflammation. Ann. Surg. 2, 479-485 (1885).
3. Lefer, A. M. & Rovetto, M. J. Influence of a myocardial depressant factor on physiologic properties of cardiac muscle. Proc. Soc. Exp. Biol. Med. 134, 269-273 (1970).
4. Lefer, A. M., Cowgill, R., Marshall, F. F., Hall, L. M. & Brand, E. D. Characterization of a myocardial depressant factor present in hemorrhagic shock. Am. J. Physiol. 213, 492-498 (1967).
5. Brand, E. D. & Lefer, A. M. Myocardial depressant factor in plasma from cats in irreversible post-oligemic shock. Proc. Soc. Exp. Biol. Med. 122, 200-203 (1966).
6. Arslan, F., de Kleijn, D. P., Timmers, L., Doevendans, P. A. & Pasterkamp, G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr. Pharm. Des. 14, 1205-1216 (2008). (Pubitemid 351997833)
7. Chao, W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am. J. Physiol. Heart Circ. Physiol. 296, H1-12 (2009).
8. Frangogiannis, N. G. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm. Res. 53, 585-595 (2004). (Pubitemid 40385316)
9. Kelly, R. A. & Smith, T. W. Cytokines and cardiac contractile function. Circulation 95, 778-781 (1997). (Pubitemid 27091510)
10. Mann, D. L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91, 988-998 (2002). (Pubitemid 35416635)
11. Frangogiannis, N. G. The immune system and cardiac repair. Pharmacol. Res. 58, 88-111 (2008).
12. Rezkalla, S. H. & Kloner, R. A. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter. Cardiovasc. Interv. 72, 950-957 (2008).
13. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc. Res. 61, 481-497 (2004). (Pubitemid 38210154)
14. Dobaczewski, M., Gonzalez-Quesada, C. & Frangogiannis, N. G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J. Mol. Cell Cardiol. 48, 504-511 (2009).
15. Spinale, F. G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87, 1285-1342 (2007). (Pubitemid 350041472)
16. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301-305 (2002). (Pubitemid 34303674)
17. Seong, S. Y. & Matzinger, P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469-478 (2004). (Pubitemid 38745558)
18. Ionita, M. G., Arslan, F., de Kleijn, D. P. & Pasterkamp, G. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. J. Innate. Immun. 2, 307-315 (2010).
19. Blasius, A. L. & Beutler, B. Intracellular toll-like receptors. Immunity 32, 305-315 (2010).
20. Arslan, F. et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 121, 80-90 (2010).
21. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004). (Pubitemid 38931765)
22. Hansson, G. K. Immune and inflammatory mechanisms in the development of atherosclerosis. Br. Heart J. 69, S38-S41 (1993). (Pubitemid 23035605)
23. Brodison, A. & Swann, J. W. Myocarditis: a review. J. Infect. 37, 99-103 (1998). (Pubitemid 28482908)
24. Hansson, G. K. & Edfeldt, K. Toll to be paid at the gateway to the vessel wall. Arterioscler. Thromb. Vasc. Biol. 25, 1085-1087 (2005). (Pubitemid 40776589)
25. Li, M., Zhou, Y., Feng, G. & Su, S. B. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr. Mol. Med. 9, 365-374 (2009).
26. Frantz, S., Ertl, G. & Bauersachs, J. Toll-like receptor signaling in the ischemic heart. Front. Biosci. 13, 5772-5779 (2008).
27. Kumar, H., Kawai, T. & Akira, S. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 388, 621-625 (2009).
28. Arslan, F., Keogh, B., McGuirk, P. & Parker, A. E. TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm. doi:10.1155/2010/704202.
29. Favre, J. et al. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 27, 1064-1071 (2007). (Pubitemid 46641958)
30. Knuefermann, P. et al. Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 110, 3693-3698 (2004). (Pubitemid 39665259)
31. Boyd, J. H., Mathur, S., Wang, Y., Bateman, R. M. & Walley, K. R. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc. Res. 72, 384-393 (2006). (Pubitemid 44665856)
32. Sakata, Y. et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 292, H503-H509 (2007). (Pubitemid 46105213)
33. Landmesser, U., Wollert, K. C. & Drexler, H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc. Res. 81, 519-527 (2009).
34. Cohn, J. N., Ferrari, R. & Sharpe, N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35, 569-582 (2000). (Pubitemid 30167013)
35. Shishido, T. et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108, 2905-2910 (2003). (Pubitemid 37517819)
36. Timmers, L. et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ. Res. 102, 257-264 (2008). (Pubitemid 351674064)
37. Satoh, M. et al. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int. J. Cardiol. 109, 226-234 (2006).
38. Timmers, L. et al. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ. Res. 104, 699-706 (2009).
39. Piper, H. M., Abdallah, Y. & Schafer, C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc. Res. 61, 365-371 (2004). (Pubitemid 38210144)
40. Eefting, F. et al. Role of apoptosis in reperfusion injury. Cardiovasc. Res. 61, 414-426 (2004). (Pubitemid 38210148)
41. Inserte, J., Barrabes, J. A., Hernando, V. & Garcia-Dorado, D. Orphan targets for reperfusion injury. Cardiovasc. Res. 83, 169-178 (2009).
42. Gustafsson, A. B. & Gottlieb, R. A. Heart mitochondria: gates of life and death. Cardiovasc. Res. 77, 334-343 (2008). (Pubitemid 351197632)
43. Garrido, C., Gurbuxani, S., Ravagnan, L. & Kroemer, G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem. Biophys. Res. Commun. 286, 433-442 (2001). (Pubitemid 32912965)
44. Kol, A., Lichtman, A. H., Finberg, R. W., Libby, P. & Kurt-Jones, E. A. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J. Immunol. 164, 13-17 (2000). (Pubitemid 30012965)
45. Ohashi, K., Burkart, V., Flohe, S. & Kolb, H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164, 558-561 (2000). (Pubitemid 30043672)
46. Tissieres, A., Mitchell, H. K. & Tracy, U. M. Protein synthesis in salivary glands of Drosophila melanogaster: relation to chromosome puffs. J. Mol. Biol. 84, 389-398 (1974).
47. Young, J. C. Mechanisms of the Hsp70 chaperone system. Biochem. Cell. Biol. 88, 291-300 (2010).
48. Daugaard, M., Rohde, M. & Jaattela, M. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett. 581, 3702-3710 (2007). (Pubitemid 47081009)
49. Currie, R. W. & White, F. P. Trauma-induced protein in rat tissues: a physiological role for a "heat shock" protein? Science 214, 72-73 (1981). (Pubitemid 11031360)
50. Currie, R. W. Effects of ischemia and perfusion temperature on the synthesis of stress-induced (heat shock) proteins in isolated and perfused rat hearts. J. Mol. Cell Cardiol. 19, 795-808 (1987). (Pubitemid 17144744)
51. Yellon, D. M. & Latchman, D. S. Stress proteins and myocardial protection. J. Mol. Cell Cardiol. 24, 113-124 (1992).
52. Gupta, M., Vavasis, C. & Frishman, W. H. Heat shock proteins in cardiovascular disease a new therapeutic target. Cardiol. Rev. 12, 26-30 (2004). (Pubitemid 38020149)
53. Fan, G. C., Chu, G. & Kranias, E. G. Hsp20 and its cardioprotection. Trends Cardiovasc. Med. 15, 138-141 (2005). (Pubitemid 41138877)
54. Tanonaka, K., Yoshida, H., Toga, W., Furuhama, K. & Takeo, S. Myocardial heat shock proteins during the development of heart failure. Biochem. Biophys. Res. Commun. 283, 520-525 (2001). (Pubitemid 32924722)
55. Knowlton, A. A. et al. Differential expression of heat shock proteins in normal and failing human hearts. J. Mol. Cell Cardiol. 30, 811-818 (1998). (Pubitemid 28190725)
56. Yellon, D. M. et al. Whole body heat stress fails to limit infarct size in the reperfused rabbit heart. Cardiovasc. Res. 26, 342-346 (1992).
57. Legare, J. F., Oxner, A., Heimrath, O., Myers, T. & Currie, R. W. Heat shock treatment results in increased recruitment of labeled PMN following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 293, H3210-H3215 (2007). (Pubitemid 350106549)
58. Zal, B. et al. Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation 109, 1230-1235 (2004). (Pubitemid 38372781)
59. Lin, L. et al. HSP60 in heart failure: abnormal distribution and role in cardiac myocyte apoptosis. Am. J. Physiol. Heart Circ. Physiol. 293, H2238-H2247 (2007). (Pubitemid 47605867)
60. Frantz, S. et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest. 104, 271-280 (1999).
61. Kim, S. C. et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ. Res. 105, 1186-1195 (2009).
62. Olivetti, G. et al. Apoptosis in the failing human heart. N. Engl. J. Med. 336, 1131-1141 (1997).
63. Sharma, A. K., Dhingra, S., Khaper, N. & Singal, P. K. Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs. Am. J. Physiol. Heart Circ. Physiol. 293, H1384-H1390 (2007). (Pubitemid 47367180)
64. Dorn, G. W. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc. Res. 81, 465-473 (2009).
65. Park, M. et al. Apoptosis predominates in nonmyocytes in heart failure. Am. J. Physiol. Heart Circ. Physiol. 297, H785-H791 (2009).
66. Muller, S., Ronfani, L. & Bianchi, M. E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J. Intern. Med. 255, 332-343 (2004). (Pubitemid 38315274)
67. Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002). (Pubitemid 34773774)
68. Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342 (2005). (Pubitemid 40516158)
69. Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551-5560 (2003). (Pubitemid 37279964)
70. Rendon-Mitchell, B. et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170, 3890-3897 (2003). (Pubitemid 36361997)
71. Chen, G. et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through. J. Leukoc. Biol. 76, 994-1001 (2004). (Pubitemid 39462000)
72. Li, W., Sama, A. E. & Wang, H. Role of HMGB1 in cardiovascular diseases. Curr. Opin. Pharmacol. 6, 130-135 (2006). (Pubitemid 43362125)
73. Park, J. S. et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004). (Pubitemid 38294612)
74. Ivanov, S. et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110, 1970-1981 (2007). (Pubitemid 47443911)
75. Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496 (2007). (Pubitemid 46605917)
76. Kohno, T. et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc. Res. 81, 565-573 (2009).
77. Takahashi, K. et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 118, S106-S114 (2008).
78. Goldstein, R. S. et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25, 571-574 (2006). (Pubitemid 44297016)
79. Kitahara, T. et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc. Res. 80, 40-46 (2008).
80. Limana, F. et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ. Res. 97, e73-e83 (2005).
81. Rossini, A. et al. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J. Mol. Cell Cardiol. 44, 683-693 (2008).
82. Andrassy, M. et al. High-mobility group Box-1 in ischemia-reperfusion injury of the heart. Circulation 117, 3216-3226 (2008).
83. Tzeng, H. P. et al. Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 294, H1490-H1496 (2008).
84. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999). (Pubitemid 29329996)
85. Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl Acad. Sci. USA 101, 296-301 (2004). (Pubitemid 38084244)
86. Natanson, C. et al. Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J. Clin. Invest. 83, 243-251 (1989). (Pubitemid 19048430)
87. Ono, M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 99, 1501-1506 (2008).
88. vid Dong, Z. M., Aplin, A. C. & Nicosia, R. F. Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells. Curr. Pharm. Des. 15, 365-379 (2009).
89. Srikrishna, G. & Freeze, H. H. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11, 615-628 (2009).
90. Sharma, A., Ray, R. & Rajeswari, M. R. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest. 26, 843-851 (2008).
91. Dobaczewski, M. et al. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res. 324, 475-488 (2006). (Pubitemid 43673489)
92. Comper, W. D. & Laurent, T. C. Physiological function of connective tissue polysaccharides. Physiol. Rev. 58, 255-315 (1978). (Pubitemid 9081040)
93. Waldenstrom, A., Martinussen, H. J., Gerdin, B. & Hallgren, R. Accumulation of hyaluronan and tissue edema in experimental myocardial infarction. J. Clin. Invest. 88, 1622-1628 (1991).
94. Termeer, C. et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 195, 99-111 (2002). (Pubitemid 34074500)
95. Scheibner, K. A. et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 177, 1272-1281 (2006). (Pubitemid 44036633)
96. Gariboldi, S. et al. Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. J. Immunol. 181, 2103-2110 (2008).
97. Jiang, D. et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 11, 1173-1179 (2005). (Pubitemid 43093664)
98. Zheng, L., Riehl, T. E. & Stenson, W. F. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology 137, 2041-2051 (2009).
99. Liao, Y. F., Gotwals, P. J., Koteliansky, V. E., Sheppard, D. & Van De, W. L. The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J. Biol. Chem. 277, 14467-14474 (2002). (Pubitemid 34952511)
100. Schoneveld, A. H. et al. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 197, 95-104 (2008). (Pubitemid 351273277)
101. Arslan F. et al. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ. Res. 108, 582-592 (2011).
102. Li, Y., Heuser, J. S., Cunningham, L. C., Kosanke, S. D. & Cunningham, M. W. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J. Immunol. 177, 8234-8240 (2006). (Pubitemid 44846345)
103. Fairweather, D. et al. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J. Immunol. 176, 3516-3524 (2006). (Pubitemid 43363999)
104. Zhang, P., Cox, C. J., Alvarez, K. M. & Cunningham, M. W. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J. Immunol. 183, 27-31 (2009).
105. Erridge, C. & Samani, N. J. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler. Thromb. Vasc. Biol. 29, 1944-1949 (2009).
106. Tsan, M. F. & Gao, B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76, 514-519 (2004). (Pubitemid 39129081)
107. Tsan, M. F. & Baochong, G. Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J. Endotoxin. Res. 13, 6-14 (2007).
108. Zhu, X. et al. Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit. Care Med. 35, 886-892 (2007). (Pubitemid 46407806)
109. Schoneveld, A. H. et al. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc. Res. 66, 162-169 (2005). (Pubitemid 40357879)
110. Bjorkbacka, H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr. Opin. Lipidol. 17, 527-533 (2006). (Pubitemid 44372683)
111. Hardarson, H. S. et al. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am. J. Physiol. Heart Circ. Physiol. 292, H251-H258 (2007). (Pubitemid 46105186)
112. Richer, M. J., Lavallee, D. J., Shanina, I. & Horwitz, M. S. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One 4, e4127 (2009).
113. Oyama, J. et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109, 784-789 (2004). (Pubitemid 38222900)
114. Fairweather, D. et al. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta- and IL-18-associated myocarditis and coxsackievirus replication. J. Immunol. 170, 4731-4737 (2003). (Pubitemid 36519981)
115. Vink, A. et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106, 1985-1990 (2002). (Pubitemid 35176306)
116. Triantafilou, K. et al. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol. 7, 1117-1126 (2005). (Pubitemid 41030937)
117. Yu, Q. et al. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am. J. Physiol. Heart Circ. Physiol. 297, H76-H85 (2009).
118. Bulicheva, N. et al. Effect of cell-free DNA of patients with cardiomyopathy and rDNA on the frequency of contraction of electrically paced neonatal rat ventricular myocytes in culture. Ann. N. Y. Acad. Sci. 1137, 273-277 (2008).
119. Knuefermann, P. et al. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc. Res. 78, 26-35 (2008). (Pubitemid 351430962)
120. Chen, L. et al. TLR signals promote IL-6/IL-17-dependent transplant rejection. J. Immunol. 182, 6217-6225 (2009).